Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 374 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Extraction Phase Clear all
Completed Phase 2 Interventional Results available

Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

NCT00964431
View directory record Official record
Conditions
Dental Pain
Interventions
Celecoxib 400 mg, Placebo, Indomethacin Test (lower dose), Indomethacin Test (upper dose)
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 3 Interventional

Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

NCT04962139
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
ON101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Mesa, Arizona • Carlsbad, California • Castro Valley, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 28, 2026, 3:09 PM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

NCT01450657
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics/Renadyl
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

A Second Trial of the Abbreviated Protocol Two-Stage Exchange

NCT05607030
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
VT-X7 Treatment System, Two-stage exchange arthroplasty, SOC Antibiotics, Experimental Antibiotics
Combination Product · Procedure · Drug
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Sarasota, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Results available

The Capillary Index Score Trial

NCT02618031
View directory record Official record
Conditions
Acute Stroke, Brain Ischemia, Ischemic Stroke
Interventions
Endovascular Treatment (EVT)
Procedure
Lead sponsor
Firas Al-Ali
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Atlanta, Georgia • New York, New York • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 28, 2026, 3:09 PM EDT
Active, not recruiting Not applicable Interventional

Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing

NCT06805877
View directory record Official record
Conditions
HIV
Interventions
Predictive Analytics and Clinical Decision Support
Other
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Fremont, California • Oakland, California • Oceanside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Enrolling by invitation No phase listed Observational

Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease

NCT02040714
View directory record Official record
Conditions
Legg Calve Perthes Disease
Interventions
Osteotomy + Long Term Non-Weight Bearing, Osteotomy + Short Term Non-Weight Bearing, Nonoperative Observation, Multiple Epiphyseal Drilling
Procedure
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
1 Year to 18 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

NCT03234400
View directory record Official record
Conditions
HIV-1-infection
Interventions
Dapivirine Vaginal Ring, 25 mg, Dapivirine Vaginal Ring, 100 mg, Dapivirine Vaginal Ring, 200 mg
Combination Product
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral
Interventions
Romidepsin, Ixazomib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional Results available

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

NCT03406715
View directory record Official record
Conditions
Small Cell Lung Cancer, Lung Cancer, Relapsed Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Dendritic Cell based p53 Vaccine
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

NCT06774625
View directory record Official record
Conditions
Acute Pain, Postoperative
Interventions
LTG-001 High Dose, LTG-001 Mid Dose, LTG-001 Low Dose, Placebo, Suzetrigine
Drug · Other
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

NCT00805376
View directory record Official record
Conditions
Brain Cancer, Central Nervous System Diseases
Interventions
DNX-2401, Tumor Removal
Drug · Procedure
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain

NCT02837952
View directory record Official record
Conditions
Pain
Interventions
FDC IBU/APAP 250 mg/500 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 28, 2026, 3:09 PM EDT
Enrolling by invitation Phase 1 Interventional

Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

NCT04399876
View directory record Official record
Conditions
Prostate Cancer, Radical Prostatectomy
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Recruiting Phase 2 Interventional

Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction

NCT06831149
View directory record Official record
Conditions
Squamous Cell Carcinoma, Pharyngocutaneous Fistula
Interventions
Removal of pharyngeal mucosa with decreased perfusion will be performed, SPY-PHI, ICG (Indocyanine Green)
Procedure · Device · Drug
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

NCT00825916
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

NCT00462943
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Omacetaxine mepesuccinate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 28, 2026, 3:09 PM EDT
Active, not recruiting Phase 2 Interventional

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

NCT05672173
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Ibrutinib, Lisocabtagene Maraleucel, Nivolumab, Pheresis, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Liver Transplantation With Tregs at UCSF

NCT03654040
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

NCT01107236
View directory record Official record
Conditions
Healthy
Interventions
IW-6118, Matching Placebo, Naproxen Sodium
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas

NCT01240304
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation therapy, pancreaticoduodenectomy
Drug · Radiation · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional

A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors

NCT01351519
View directory record Official record
Conditions
Malignant Glioma, Glioma, Glioblastoma, Glioblastoma Multiforme, Astrocytoma
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 28, 2026, 3:09 PM EDT